Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. Among authors: backer v. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.
Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, Kelsen S, Eich A, Ludwig-Sengpiel A, Hupp GC, Backer V, Porsbjerg C, Girodet PO, Berger P, Leigh R, Kline JN, Dransfield M, Calhoun W, Hussaini A, Khatri S, Chanez P, Susulic VS, Barnathan ES, Curran M, Das AM, Brodmerkel C, Baribaud F, Loza MJ. Silkoff PE, et al. Among authors: backer v. Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y. Respir Res. 2015. PMID: 26576744 Free PMC article.
Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; ADEPT Investigators. Silkoff PE, et al. Among authors: backer v. Respir Res. 2016 Apr 23;17:43. doi: 10.1186/s12931-016-0360-5. Respir Res. 2016. PMID: 27107814 Free PMC article. Clinical Trial.
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg CM, Girodet PO, Berger P, Kline JN, Chupp G, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study investigators. Silkoff PE, et al. Among authors: backer v. J Allergy Clin Immunol. 2017 Sep;140(3):710-719. doi: 10.1016/j.jaci.2016.11.038. Epub 2017 Jan 13. J Allergy Clin Immunol. 2017. PMID: 28089872 Clinical Trial.
Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study.
Silkoff PE, Flavin S, Gordon R, Loza MJ, Sterk PJ, Lutter R, Diamant Z, Turner RB, Lipworth BJ, Proud D, Singh D, Eich A, Backer V, Gern JE, Herzmann C, Halperin SA, Mensinga TT, Del Vecchio AM, Branigan P, San Mateo L, Baribaud F, Barnathan ES, Johnston SL. Silkoff PE, et al. Among authors: backer v. J Allergy Clin Immunol. 2018 Apr;141(4):1220-1230. doi: 10.1016/j.jaci.2017.06.027. Epub 2017 Jul 20. J Allergy Clin Immunol. 2018. PMID: 28734844 Free article. Clinical Trial.
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation.
Silkoff PE, Singh D, FitzGerald JM, Eich A, Ludwig-Sengpiel A, Chupp GC, Backer V, Porsbjerg C, Girodet PO, Dransfield MT, Baribaud F, Susulic VS, Loza MJ. Silkoff PE, et al. Among authors: backer v. Biomark Insights. 2017 Sep 7;12:1177271917730306. doi: 10.1177/1177271917730306. eCollection 2017. Biomark Insights. 2017. PMID: 28959121 Free PMC article.
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators. Russell RJ, et al. Among authors: backer v. Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21. Lancet Respir Med. 2018. PMID: 29793857 Clinical Trial.
467 results